CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Pulmobiotics focuses on developing a novel treatment for non-small-cell lung cancer using a modified strain of Mycoplasma pneumoniae to enhance immune response. The project aims to create a product that improves the effectiveness of existing immunotherapies for patients.
Non-small-cNon-small-cell carcinomas (NSCLC) represent 80-85% of the worldwide lung cancer cases, which are the leading cause of cancer-related death.
Several clinical trials have indicated better survival rates in NSCLC patients treated with immune checkpoint inhibitor (ICI) antibodies targeting PD-1/PD-L1 or CTLA4.
However, since many patients display innate or acquired resistance to these therapies, there is a pressing need to discover methods to help them overcome the resistance.
Founders of…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
